Renin-angiotensin system inhibitors and atrial fibrillation

Israel Medical Association Journal

Volumn 7, Issue 6, 2005, Pages 388-391

  Arbel, Yaron ^a,b   Glikson, Michael ^a,b  

^a SHEBA MEDICAL CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

Author keywords

Angiotensin; Angiotensin converting enzyme inhibitors; Atrial fibrillation; Cardioversion; Tachyarrhythmias

Indexed keywords

AMIODARONE; ANGIOTENSIN; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN RECEPTOR ANTAGONIST; ANGIOTENSINOGEN; ANTIARRHYTHMIC AGENT; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CANDESARTAN; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; HYDRALAZINE; IRBESARTAN; ISOSORBIDE MONONITRATE; LOSARTAN; MITOGEN ACTIVATED PROTEIN KINASE; PLACEBO; PROTEIN BAX; PROTEIN BCL 2; TRANDOLAPRIL;

AGE; ANTIARRHYTHMIC ACTIVITY; APOPTOSIS; ARRHYTHMOGENESIS; ARTICLE; CARDIOVERSION; CLINICAL TRIAL; DEFIBRILLATION; DOSE RESPONSE; DRUG EFFICACY; DRUG MECHANISM; GENETIC POLYMORPHISM; HEART ATRIUM FIBRILLATION; HEART ATRIUM PACING; HEART FAILURE; HUMAN; HYPERTENSION; META ANALYSIS; NONHUMAN; PRESCRIPTION; PREVALENCE; PRIMARY PREVENTION; PROTEIN EXPRESSION; RADIOFREQUENCY ABLATION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RISK REDUCTION; SIGNAL TRANSDUCTION; SYSTEMATIC REVIEW; VASCULAR DISEASE;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; ATRIAL FIBRILLATION; HUMANS;

EID: 20844439730     PISSN: 15651088     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Feinberg WM, Blackshear JL, Laupacis A, et al. Prevalence, age distribution, and gender of patients with atrial fibrillation: analysis and implications. Arch Intern Med 1995;155:469-73.
2. Krahn AD, Manfrecla J, Tate RB, Mathewson FA, Cuddy TE. The natural history of atrial fibrillation: incidence, risk factors, and prognosis in the Manitoba follow-up group. Am J Med 1995; 98:476-84.
3. Haïssaguerre M, Jaïs P, Shah DC, et al. Spontaneous initiation of atrial fibrillation by ectopic beats originating in the pulmonary veins. N Engl J Med 1998;339659-66.
4. Nattel S. New ideas about atrial fibrillation 50 years on. Nature 2002;415:219-26.
5. Wijffels MCEF, Kirchlof CJHJ, Dorland R, Allessie M. Atrial fibrillation begets atrial fibrillation: a study in awake chronically instrumented goats. Circulation 1995;92:1954-68.
6. Madrid AH, Bueno MG, Rebollo JMG, et al. Use of Irbesartan to maintain sinus rhythm in patients with long-lasting persistent atrial fibrillation. A prospective and randomized study Circulation 2002;106:331-6.
7. Allessie MA. Atrial electrophysiological remodeling. Another viscious cycle? J Cardiovasc Electrophysiol 1998;9:1378-93.
8. Madrid AH, Marin IM, Cervantes CE, et al. Prevention of recurrences in patients with lone atrial fibrillation. The close-dependent effect of angiotensin II receptor blockers. J Renin Angiotensin Aldosterone Syst 2004;5:114-20.
9. Villani G, Piepoli M, Terracciano C, et al. Effects of diltiazem pretreatment on direct-current cardioversion in patients with persistent atrial fibrillation: a single blind, randomized, controlled study. Am Heart J 2000;140:437-43.
10. Simone A, Stabile G, Vitale DF, et al. Pretreatment with verapamil in patients with persistent or chronic atrial fibrillation who underwent electrical cardioversion. J Am Coll Cardiol 1999;34:810-14.
11. Kühlkamp V, Schirdewan A, Stangl K, et al. Use of metoprolol CR/XL to maintain sinus rhythm after conversion from persistent atrial fibrillation. J Am Coll Cardiol 2000;36:139-46.
12. Workman AJ, Kane KA, Russell JA, Norrie J, Rankin AC. Chronic beta-adrenoceptor blockade and human atrial cell electrophysiology: evidence of pharmacological remodeling Cardiovasc Res 2003;58:518-25.
13. Pedersen OD, Bagger H, Kober L, et al. Trandolapril reduces the incidence of atrial fibrillation after acute myocardial infarction in patients with left ventricular dysfunction. Circulation 1999;100: 376-80.
14. Vermes E, Tardif JC, Bourassa MG, et al. Enalapril decreases the incidence of atrial fibrillation in patients with left ventricular dysfunction. Circulation 2003;107:2926-31.
15. Capucci A, Villani GQ, Aschieri D, et al. Oral anniodarone in creases the efficacy of direct-current cardioversion in restoration of sinus rhythm in patients with chronic atrial fibrillation. Eur Heart J 2000;21:66-73.
16. Ueng KC, Tsai TP, Yu WC, et al. Use of enalapril to facilitate sinus rhythm maintenance after external cardioversion of longstanding persistent atrial fibrillation. Eur Heart J 2003;24:2090-8.
17. Lindholm LH, Dahlöf B, Edelman JM, et al. Effect of losartan on sudden cardiac death in people with diabetes: data from the LIFE study. Lancet 2003;362:619-20.
18. Nakashima H, Kumagai K, Urata H, Condo N, Ideishi M, Arakawa K. Angiotensin II antagonist prevents electrical remodeling in atrial fibrillation. Circulation 2000;101:2612-17.
19. Li D, Shinagawa K, Pang L, et al. Effects of angiotensin-converting enzyme inhibition on the development of the atrial fibrillation substrate in dogs with ventricular tachypacing-induced congestive heart failure. Circulation 2001;1042608-14.
20. Klein L, O'Connor CM, Gattis WA, et al. Pharmacologic therapy for patients with chronic heart failure and reduced systolic function: review of trial and practical considerations. Am J Cardiol 2003;91(Suppl):18-40F.
21. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin converting-enzyme inhibitor, ramipril, on death from cardiovascular causes, myocardial infarction and stroke in high-risk patients. N Engl J Med 2000;342:145-53.
22. The European Trial on Reduction of Cardiac Events with Perindopril in Stable Coronary Artery Disease. Efficacy of perinclopril in reduction of cardiovascular events among patients with stable coronary artery disease randomized, double-blind, placebo-controlIed, multicenter trial (the EUROPA study). Lancet 2003;362:782-8.
23. Pandozi C, Santini M. Update on atrial remodeling owing to rate Eur Heart J 2001;22:541-53.
24. Cardin S, Li D, Thorin-Trescases N, et al. Evolution of the atrial fibrillation substrate in experimental congestive heart failure: angiotensin-dependent and independent pathways. Cardiovasc Res 2003;160(2):315-25.
25. Goette A, Staack T, Rocken C, et al. increased expression of extracellular signal-regulated kinase and angiotensin-converting enzyme in human atria during atrial fibrillation. J Am Coll Cardiol 2000;35:1669-77.
26. Yano M, Kim S, Izumi Y, et al. Differential activation of cardiac c-Jun amino-terminal kinase and extracellular signal-regulated kinase in angiotensin II-mediated hypertension. Circ Res 1998;83:752-60.
27. Sugden PH, Clerk A. Cellular mechanisms of cardiac hypertrophy. J Mol Med 1998;76:725-46.
28. Komuro I, Kaida T, Shibazaki Y, et al. Stretching cardiac myocytes stimulates proto-oncogene expression. J Biol Chem 1990;265: 3595-8.
29. Tsai CT, Lai LP, Lin JL, et al. Renin-angiotensin system gene polymorphisms and atrial fibrillation. Circulation 2004;109: 1640-6.
30. Dalhöf B, et al. Presented at the European Society of Cardiology Congress, Berlin. August 2002. Poster 2163.
31. L'Allier PL, Ducharme A, Keller PF, et al. Angiotensin-converting enzyme inhibition in hypertensive patients is associated with a reduction in the occurrence of atrial fibrillation. J Am Coll Cardiol 2004;44:159-64.
32. Zaman AG, Kearney MT, Schecter C, Worthley SG, Nolan J. Angiotensin-converting enzyme inhibitors as adjunctive therapy in patients with persistent atrial fibrillation. Am Heart J 2004;147:823-7.
33. Al-Khatib SM. Angiotensin-converting enzyme inhibitors: a new therapy for atrial fibrillation? Am Heart J 2004;147:751-2.
34. Madrid AH, Peng J, Zamora J, et al. The role of angiotensin receptor blockers and/or angiotensin converting enzyme inhibitors in the prevention of atrial fibrillation in patients with cardiovascular diseases: meta-analysis of randomized controlled clinical trials. Pacing Clin Electrophysiol 2004;27:1405-10.